Signaling revealed by mapping molecular interactions: Implications for ErbB-targeted cancer immunotherapies

György Vereb, Péter Nagy, John W. Park, János Szöllosi

Research output: Review article

9 Citations (Scopus)


The ErbB2 (HER2) protein is a member of the EGF receptor (ErbB) family of transmembrane receptor tyrosine kinases. Although no direct ligand has yet been assigned to ErbB2, recent biochemical and biophysical evidence suggests that this protein operates as a shared receptor subunit with other ErbB proteins. Its medical importance stems form its frequent overexpression in breast and other cancers, resulting in various tumorigenic phenotypic changes, including higher transforming activity, metastatic potential, angiogenesis and drug resistance. The multitude of possible small-scale and large-scale interactions among the ErbB proteins makes them especially diverse and important in initiating and directing signal transduction. The mechanisms of homo- and hetero-associations among ErbB proteins in the cell membrane in relation to signal transduction events remain a critical focus of investigation. Recent studies to map the molecular interactions involved in the ErbB signaling network are elucidating these mechanisms, and promise to facilitate the development of new ErbB-targeted therapies, including approaches using antibodies, immunoliposomes, cancer vaccines, gene therapy and small molecule inhibitors.

Original languageEnglish
Pages (from-to)169-186
Number of pages18
JournalClinical and Applied Immunology Reviews
Issue number3
Publication statusPublished - jún. 1 2002

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Signaling revealed by mapping molecular interactions: Implications for ErbB-targeted cancer immunotherapies'. Together they form a unique fingerprint.

  • Cite this